Stada Arz increases its stake in Pymepharco in Vietnam
German drugmaker Stada Arzneimittel (SAZ: Xetra) has increased its indirect shareholding in the Vietnamese pharmaceutical company Pymepharco JSC to 72%, in which it has been a strategic since 2008.
“Vietnam is one of the key growth markets in Asia where we want to continually expand in the future. Our extended investment in Pymepharco is an excellent basis for this," says Peter Goldschmidt, who took over as chief executive of Stada on September 1.
Vietnam is one of the most attractive pharmaceutical markets in this region, with consistent double-digit growth in recent years and currently an equally stable outlook,according to Stada. In 2016, Stada achieved sales in Vietnam in the three-digit million euro range. Pymepharco stands to play a stronger role in the development of neighboring Southeast Asia markets in the future.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze